Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Saliva Diagnostic Systems v. Home Access Health

This article was originally published in The Gray Sheet

Executive Summary

Saliva Diagnostic Systems v. Home Access Health: Home Access files counterclaim June 10 in the Clark County Superior Court of Washington state seeking damages "in excess of $3 mil." in response to SDS' "attempt to pursue cancellation" of a license agreement between the two firms relating to SDS' Omni-Sal saliva collection device. SDS filed suit in January requesting the court clarify the rights negotiated in contracts between the firms regarding the Omni-Sal, for which Home Access obtained exclusive rights in March 1995 ("The Gray Sheet" March 27, 1995, In Brief). Home Access planned to use the technology to develop a home HIV sample collection device. The firm's blood-based home collection HIV test currently is in the "final stages" of FDA review...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT006184

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel